{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:47:45Z","timestamp":1793130465932,"version":"4.5.0"},"reference-count":235,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In July 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired.<\/jats:p>\n                  <jats:p>Background: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE).<\/jats:p>\n                  <jats:p>Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. These guidelines assume the choice of anticoagulant has already been made.<\/jats:p>\n                  <jats:p>Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <jats:p>Results: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants.<\/jats:p>\n                  <jats:p>Conclusions: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti\u2013factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018024893","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T16:54:26Z","timestamp":1543337666000},"page":"3257-3291","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":469,"title":["American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy"],"prefix":"10.1182","volume":"2","author":[{"given":"Daniel M.","family":"Witt","sequence":"first","affiliation":[{"name":"1Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby","family":"Nieuwlaat","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Clark","sequence":"additional","affiliation":[{"name":"3Clinical Pharmacy Anticoagulation and Anemia Service, Kaiser Permanente Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Ansell","sequence":"additional","affiliation":[{"name":"4School of Medicine, Hofstra Northwell, Hempstead, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Holbrook","sequence":"additional","affiliation":[{"name":"5Division of Clinical Pharmacology and Toxicology, Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Skov","sequence":"additional","affiliation":[{"name":"6Unit for Health Promotion Research, Department of Public Health, University of Southern Denmark, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Shehab","sequence":"additional","affiliation":[{"name":"7Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Mock","sequence":"additional","affiliation":[{"name":"8Aurora Medical Center Summit, Summit, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarra","family":"Myers","sequence":"additional","affiliation":[{"name":"9Cambridge, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[{"name":"10Department of Medicine and Surgery, Insubria University, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Crowther","sequence":"additional","affiliation":[{"name":"11Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"12Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Bhatt","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Khatib","sequence":"additional","affiliation":[{"name":"13Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Riva","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"14Department of Family Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-0641","authenticated-orcid":false,"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"2Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2023112113304126800_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016;42(2):296-311]","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2023112113304126800_bib2","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2023112113304126800_bib3","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2023112113304126800_bib4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2023112113304126800_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2023112113304126800_bib6","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2023112113304126800_bib7","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2023112113304126800_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations. I: Critical appraisal of existing approaches","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2023112113304126800_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2023112113304126800_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2023112113304126800_bib11","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2023112113304126800_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"suppl 2","key":"2023112113304126800_bib13","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published corrections appear in Chest. 2012;141(5):1369 and Chest. 2013;144(2):721].","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"suppl 2","key":"2023112113304126800_bib14","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"suppl 2","key":"2023112113304126800_bib15","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest. 2012;141(5):1369]","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"issue":"suppl 2","key":"2023112113304126800_bib16","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"2023112113304126800_bib17","volume-title":"Conflict of Interest in Medical Research, Education, and Practice","author":"Lo","year":"2009"},{"issue":"11","key":"2023112113304126800_bib18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2023112113304126800_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2023112113304126800_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society Policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2023112113304126800_bib21","unstructured":"Bro\u017cek J , NowakA, KunstmanP, Sch\u00fcnemannHJ. GRADEpro Guideline Development Tool (G2DT). Accessed 17 July 2018. Available at: www.guidelinedevelopment.org."},{"issue":"4","key":"2023112113304126800_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2023112113304126800_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1538-7836.2004.01053.x","article-title":"The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients","volume":"3","author":"Al-Yaseen","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2023112113304126800_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1538-7836.2012.04727.x","article-title":"A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)","volume":"10","author":"Cosmi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2023112113304126800_bib25","first-page":"739","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"2023112113304126800_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am Heart J"},{"issue":"1","key":"2023112113304126800_bib27","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"issue":"4","key":"2023112113304126800_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjcard.2017.05.026","article-title":"Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF Trial)","volume":"120","author":"Washam","year":"2017","journal-title":"Am J Cardiol"},{"key":"2023112113304126800_bib29","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2023112113304126800_bib30","first-page":"518","article-title":"Results of the first randomized French study evaluating self-testing of the international normalized ratio","volume":"20","author":"Azarnoush","year":"2011","journal-title":"J Heart Valve Dis"},{"issue":"9","key":"2023112113304126800_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-133-9-200011070-00010","article-title":"A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial","volume":"133","author":"Beyth","year":"2000","journal-title":"Ann Intern Med"},{"issue":"3","key":"2023112113304126800_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/tmj.2010.0128","article-title":"Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment","volume":"17","author":"Christensen","year":"2011","journal-title":"Telemed J E Health"},{"issue":"21","key":"2023112113304126800_bib33","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1001\/archinte.163.21.2639","article-title":"Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in The Netherlands: a randomized clinical trial","volume":"163","author":"Gadisseur","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"2023112113304126800_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1013228718768","article-title":"Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease","volume":"5 suppl 1","author":"Horstkotte","year":"1998","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2023112113304126800_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2141.2004.05074.x","article-title":"The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation","volume":"126","author":"Khan","year":"2004","journal-title":"Br J Haematol"},{"issue":"17","key":"2023112113304126800_bib36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1002617","article-title":"Effect of home testing of international normalized ratio on clinical events","volume":"363","author":"Matchar","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2023112113304126800_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-9560-10-17","article-title":"Effects of computer-assisted oral anticoagulant therapy","volume":"10","author":"Rasmussen","year":"2012","journal-title":"Thromb J"},{"issue":"8","key":"2023112113304126800_bib38","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1538-7836.2009.03497.x","article-title":"Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system","volume":"7","author":"Ryan","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2023112113304126800_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jtcvs.2012.03.088","article-title":"Anticoagulation early after mechanical valve replacement: improved management with patient self-testing","volume":"146","author":"Thompson","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"2023112113304126800_bib40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.7326\/0003-4819-111-9-730","article-title":"Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study","volume":"111","author":"White","year":"1989","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023112113304126800_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1538-7836.2004.00659.x","article-title":"Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life","volume":"2","author":"Gadisseur","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2023112113304126800_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11239-014-1128-8","article-title":"The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial","volume":"40","author":"Matchar","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"48","key":"2023112113304126800_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19480","article-title":"The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT\/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation","volume":"19","author":"Sharma","year":"2015","journal-title":"Health Technol Assess"},{"issue":"9","key":"2023112113304126800_bib44","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11606-016-3700-8","article-title":"At-home versus in-clinic INR monitoring: a cost-utility analysis from the Home INR Study (THINRS)","volume":"31","author":"Phibbs","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"4","key":"2023112113304126800_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jval.2015.12.017","article-title":"Budget impact of increasing market share of patient self-testing and patient self-management in anticoagulation","volume":"19","author":"Stevanovi\u0107","year":"2016","journal-title":"Value Health"},{"issue":"38","key":"2023112113304126800_bib46","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11380","article-title":"Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol Assess"},{"key":"2023112113304126800_bib47","year":"2014"},{"issue":"6","key":"2023112113304126800_bib48","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1016\/j.ijcard.2013.08.054","article-title":"Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial","volume":"168","author":"Dignan","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"2023112113304126800_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejcts.2008.10.020","article-title":"Self-management program improves anticoagulation control and quality of life: a prospective randomized study","volume":"35","author":"Soliman Hamad","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"issue":"11","key":"2023112113304126800_bib50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jcp.55.11.845","article-title":"A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management","volume":"55","author":"Fitzmaurice","year":"2002","journal-title":"J Clin Pathol"},{"issue":"3","key":"2023112113304126800_bib51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1160\/TH06-08-0482","article-title":"Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial","volume":"97","author":"Siebenhofer","year":"2007","journal-title":"Thromb Haemost"},{"issue":"10","key":"2023112113304126800_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/j.1875-9114.2012.01116","article-title":"Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial","volume":"32","author":"Verret","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"7524","key":"2023112113304126800_bib53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/bmj.38618.580903.AE","article-title":"Self management of oral anticoagulation: randomised trial","volume":"331","author":"Fitzmaurice","year":"2005","journal-title":"BMJ"},{"issue":"6","key":"2023112113304126800_bib54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1592\/phco.19.9.787.31546","article-title":"Outpatient self-management of warfarin therapy: a pilot study","volume":"19","author":"Sunderji","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2023112113304126800_bib55","first-page":"e292","article-title":"Patient self-management of warfarin therapy: pragmatic feasibility study in Canadian primary care","volume":"57","author":"Grunau","year":"2011","journal-title":"Can Fam Physician"},{"issue":"1","key":"2023112113304126800_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-142-1-200501040-00006","article-title":"Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial","volume":"142","author":"Men\u00e9ndez-J\u00e1ndula","year":"2005","journal-title":"Ann Intern Med"},{"issue":"3","key":"2023112113304126800_bib57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00392-005-0199-0","article-title":"Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study)","volume":"94","author":"V\u00f6ller","year":"2005","journal-title":"Z Kardiol"},{"issue":"1","key":"2023112113304126800_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0003-4975(01)02656-X","article-title":"International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?","volume":"72","author":"K\u00f6rtke","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"2023112113304126800_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.281.2.145","article-title":"A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial","volume":"281","author":"Sawicki","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"2023112113304126800_bib60","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejim.2005.11.021","article-title":"Self-management versus conventional management of oral anticoagulant therapy: A randomized, controlled trial","volume":"17","author":"Christensen","year":"2006","journal-title":"Eur J Intern Med"},{"issue":"5","key":"2023112113304126800_bib61","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0003-4975(01)03049-1","article-title":"Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients","volume":"72","author":"Sidhu","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"9224","key":"2023112113304126800_bib62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(00)02470-3","article-title":"Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison","volume":"356","author":"Cromheecke","year":"2000","journal-title":"Lancet"},{"issue":"suppl 1","key":"2023112113304126800_bib63","first-page":"II75","article-title":"INR self-management permits lower anticoagulation levels after mechanical heart valve replacement","volume":"108","author":"Koertke","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"2023112113304126800_bib64","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.athoracsur.2004.09.012","article-title":"Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement","volume":"79","author":"Koertke","year":"2005","journal-title":"Ann Thorac Surg."},{"issue":"20","key":"2023112113304126800_bib65","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/eurheartj\/ehm391","article-title":"Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II","volume":"28","author":"Koertke","year":"2007","journal-title":"Eur Heart J"},{"issue":"5","key":"2023112113304126800_bib66","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.athoracsur.2010.06.069","article-title":"Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement","volume":"90","author":"Koertke","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"2023112113304126800_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.athoracsur.2006.08.036","article-title":"Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement","volume":"83","author":"Koertke","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"suppl 6","key":"2023112113304126800_bib68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s003920170019","article-title":"INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial) [in German]","volume":"90","author":"K\u00f6rtke","year":"2001","journal-title":"Z Kardiol"},{"key":"2023112113304126800_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2296-4-11","article-title":"SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]","volume":"4","author":"McCahon","year":"2003","journal-title":"BMC Fam Pract"},{"issue":"2","key":"2023112113304126800_bib70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/fampra\/cmq089","article-title":"Does self-management of oral anticoagulation therapy improve quality of life and anxiety?","volume":"28","author":"McCahon","year":"2011","journal-title":"Fam Pract"},{"issue":"7437","key":"2023112113304126800_bib71","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bmj.328.7437.437","article-title":"Training for patients in a randomised controlled trial of self management of warfarin treatment","volume":"328","author":"Murray","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"2023112113304126800_bib72","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.thromres.2012.06.012","article-title":"Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life","volume":"130","author":"Siebenhofer","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"2023112113304126800_bib73","first-page":"1089","article-title":"Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial","volume":"100","author":"Siebenhofer","year":"2008","journal-title":"Thromb Haemost"},{"issue":"13","key":"2023112113304126800_bib74","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1503\/cmaj.051104","article-title":"Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy","volume":"174","author":"Regier","year":"2006","journal-title":"CMAJ"},{"issue":"6","key":"2023112113304126800_bib75","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2141.2006.06243.x","article-title":"Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis","volume":"134","author":"Jowett","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2023112113304126800_bib76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.110.960096","article-title":"Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care","volume":"4","author":"Rose","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"2023112113304126800_bib77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.14273","article-title":"Predictors of anticoagulation quality in 15 834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients","volume":"175","author":"Schaefer","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2023112113304126800_bib78","doi-asserted-by":"crossref","first-page":"e0144314","DOI":"10.1371\/journal.pone.0144314","article-title":"Center-related determinants of VKA anticoagulation quality: a prospective, multicenter evaluation","volume":"10","author":"Tosetto","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2023112113304126800_bib79","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1309\/U7164E0XH5UERKRV","article-title":"A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment","volume":"120","author":"Pengo","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2023112113304126800_bib80","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7326\/0003-4819-155-10-201111150-00003","article-title":"Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial","volume":"155","author":"Schulman","year":"2011","journal-title":"Ann Intern Med"},{"issue":"13","key":"2023112113304126800_bib81","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.113.002601","article-title":"National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation","volume":"129","author":"Dlott","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"2023112113304126800_bib82","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2257.2000.00315.x","article-title":"INR: intervals of measurement can safely extend to 14 weeks","volume":"22","author":"Lidstone","year":"2000","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"2023112113304126800_bib83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.thromres.2006.10.001","article-title":"The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation","volume":"120","author":"Shalev","year":"2007","journal-title":"Thromb Res"},{"issue":"9","key":"2023112113304126800_bib84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023112113304126800_bib85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res"},{"issue":"1","key":"2023112113304126800_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","article-title":"Dosage of enoxaparin among obese and renal impairment patients","volume":"116","author":"Bazinet","year":"2005","journal-title":"Thromb Res"},{"issue":"6","key":"2023112113304126800_bib87","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270003253420","article-title":"Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin","volume":"43","author":"Chow","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2023112113304126800_bib88","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ahj.2004.04.015","article-title":"Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment","volume":"148","author":"Kruse","year":"2004","journal-title":"Am Heart J"},{"issue":"10","key":"2023112113304126800_bib89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"Pautas","year":"2002","journal-title":"Drug Saf"},{"issue":"1","key":"2023112113304126800_bib90","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jppr200434114","article-title":"Renal function, peak anti-Xa levels and enoxaparin dosing","volume":"34","author":"Peng","year":"2004","journal-title":"J Pharm Pract Res."},{"issue":"5","key":"2023112113304126800_bib91","first-page":"800","article-title":"Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"issue":"4","key":"2023112113304126800_bib92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0031-1278351","article-title":"Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL\/min","volume":"18","author":"Sule","year":"2009","journal-title":"Int J Angiol"},{"issue":"10","key":"2023112113304126800_bib93","first-page":"e273","article-title":"Evaluating current recommended dose of enoxaparin in renally impaired and morbidly obese patients by monitoring anti-factor Xa levels [abstract]","volume":"34","author":"Ballew","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"10","key":"2023112113304126800_bib94","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1592\/phco.27.10.1347","article-title":"Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety","volume":"27","author":"Lachish","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2023112113304126800_bib95","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MBC.0b013e328356717f","article-title":"Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?","volume":"23","author":"Yildirim","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2023112113304126800_bib96","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1378\/chest.125.3.856","article-title":"Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin","volume":"125","author":"Thorevska","year":"2004","journal-title":"Chest"},{"issue":"3","key":"2023112113304126800_bib97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18773\/austprescr.2013.036","article-title":"Anti-Xa assays","volume":"36","author":"Barras","year":"2013","journal-title":"Aust Prescr"},{"issue":"3","key":"2023112113304126800_bib98","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1532\/LH96.05028","article-title":"How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective","volume":"11","author":"Favaloro","year":"2005","journal-title":"Lab Hematol"},{"issue":"3","key":"2023112113304126800_bib99","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/00313020500098900","article-title":"An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin","volume":"37","author":"Favaloro","year":"2005","journal-title":"Pathology"},{"issue":"7","key":"2023112113304126800_bib100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAT.0b013e32834bf5f4","article-title":"Laboratory testing of anticoagulants: the present and the future","volume":"43","author":"Favaloro","year":"2011","journal-title":"Pathology"},{"issue":"1","key":"2023112113304126800_bib101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","article-title":"Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review","volume":"68","author":"Egan","year":"2015","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"2023112113304126800_bib102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11239-011-0584-7","article-title":"Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series","volume":"32","author":"Deal","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2023112113304126800_bib103","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11239-014-1117-y","article-title":"Assessing an enoxaparin dosing protocol in morbidly obese patients","volume":"39","author":"Lalama","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2023112113304126800_bib104","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb Haemost"},{"issue":"7","key":"2023112113304126800_bib105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ajhp\/60.7.683","article-title":"Weight-based administration of dalteparin in obese patients","volume":"60","author":"Smith","year":"2003","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"2023112113304126800_bib106","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023112113304126800_bib107","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2015.07.001","article-title":"Intracranial haemorrhage in patients treated with direct oral anticoagulants","volume":"136","author":"Beynon","year":"2015","journal-title":"Thromb Res"},{"issue":"9","key":"2023112113304126800_bib108","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/jth.13051","article-title":"Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists","volume":"13","author":"Eerenberg","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2023112113304126800_bib109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/0885066614527417","article-title":"A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience","volume":"30","author":"Kumar","year":"2015","journal-title":"J Intensive Care Med"},{"issue":"2","key":"2023112113304126800_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/HPC.0000000000000042","article-title":"The real-world treatment of hemorrhages associated with dabigatran and rivaroxaban: a multicenter evaluation","volume":"14","author":"Pahs","year":"2015","journal-title":"Crit Pathw Cardiol"},{"issue":"28","key":"2023112113304126800_bib111","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"2023112113304126800_bib112","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"key":"2023112113304126800_bib113","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.wneu.2015.11.086","article-title":"New target-specific oral anticoagulants and intracranial bleeding: management and outcome in a single-center case series","volume":"88","author":"Senger","year":"2016","journal-title":"World Neurosurg"},{"issue":"1","key":"2023112113304126800_bib114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"169","author":"Granger","year":"2015","journal-title":"Am Heart J"},{"issue":"4","key":"2023112113304126800_bib115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCOUTCOMES.113.000132","article-title":"End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience","volume":"6","author":"Mahaffey","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"2023112113304126800_bib116","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacc.2014.05.028","article-title":"Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial","volume":"64","author":"Ruff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2023112113304126800_bib117","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jcpt.12438","article-title":"Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis","volume":"41","author":"Zhou","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"2023112113304126800_bib118","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1345\/aph.1L460","article-title":"Clinical outcomes and pharmacists' acceptance of a community hospital's anticoagulation management service utilizing decentralized clinical staff pharmacists","volume":"43","author":"Airee","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2023112113304126800_bib119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1472-6963-13-85","article-title":"Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics","volume":"13","author":"Arbring","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2023112113304126800_bib120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1345\/aph.1L027","article-title":"Impact of an inpatient anticoagulation management service on clinical outcomes","volume":"42","author":"Biscup-Horn","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2023112113304126800_bib121","first-page":"16","article-title":"Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic","volume":"14","author":"Chamberlain","year":"2001","journal-title":"J Am Board Fam Pract"},{"issue":"15","key":"2023112113304126800_bib122","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archinte.158.15.1641","article-title":"Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs","volume":"158","author":"Chiquette","year":"1998","journal-title":"Arch Intern Med"},{"issue":"6","key":"2023112113304126800_bib123","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11588520-000000000-00000","article-title":"Impact of a pharmacotherapeutic programme on control and safety of long-term anticoagulation treatment: a controlled follow-up study in Spain","volume":"34","author":"Duran-Parrondo","year":"2011","journal-title":"Drug Saf"},{"issue":"5","key":"2023112113304126800_bib124","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1331\/154434503322452274","article-title":"Evaluation of 4 years of clinical pharmacist anticoagulation case management in a rural, private physician office","volume":"43","author":"Ernst","year":"2003","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"2023112113304126800_bib125","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11239-011-0612-7","article-title":"A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability","volume":"32","author":"Garton","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"2023112113304126800_bib126","first-page":"625","article-title":"Benefits of a mobile, point-of-care anticoagulation therapy management program","volume":"28","author":"Gill","year":"2002","journal-title":"Jt Comm J Qual Improv"},{"issue":"3","key":"2023112113304126800_bib127","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ijpp.12148","article-title":"Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care","volume":"23","author":"Harrison","year":"2015","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"2023112113304126800_bib128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2710.2000.00262.x","article-title":"Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community","volume":"25","author":"Holden","year":"2000","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2023112113304126800_bib129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0049-3848(01)00401-7","article-title":"Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices","volume":"105","author":"Holm","year":"2002","journal-title":"Thromb Res"},{"issue":"13","key":"2023112113304126800_bib130","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2146\/ajhp120634","article-title":"Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care","volume":"70","author":"Lee","year":"2013","journal-title":"Am J Health Syst Pharm"},{"issue":"13","key":"2023112113304126800_bib131","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/ajhp\/53.13.1580","article-title":"Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions","volume":"53","author":"Lee","year":"1996","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"2023112113304126800_bib132","first-page":"111","article-title":"A collaborative care model of anticoagulation therapy in patients with stroke","volume":"16","author":"Lee","year":"2011","journal-title":"Neurol Asia"},{"issue":"8","key":"2023112113304126800_bib133","first-page":"e465","article-title":"Monitoring of international normalized ratios: comparison of community nurses with family physicians","volume":"58","author":"Levine","year":"2012","journal-title":"Can Fam Physician"},{"issue":"5","key":"2023112113304126800_bib134","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.25.5.685.63582","article-title":"Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service","volume":"25","author":"Locke","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2023112113304126800_bib135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1345\/aph.1K157","article-title":"Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care","volume":"42","author":"Nichol","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2023112113304126800_bib136","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2753.2008.01110.x","article-title":"Managing oral anticoagulation therapy by pharmacists in a specialty heart hospital","volume":"16","author":"Patel-Naik","year":"2010","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"2023112113304126800_bib137","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2710.2007.00792.x","article-title":"The impact of pharmacist-managed oral anticoagulation therapy in older veterans","volume":"32","author":"Poon","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2023112113304126800_bib138","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11096-011-9597-8","article-title":"Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand","volume":"34","author":"Saokaew","year":"2012","journal-title":"Int J Clin Pharm"},{"issue":"14","key":"2023112113304126800_bib139","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2015.2761","article-title":"Site-level variation in and practices associated with dabigatran adherence","volume":"313","author":"Shore","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"2023112113304126800_bib140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1345\/aph.1P617","article-title":"Clinical outcomes of a collaborative, home-based postdischarge warfarin management service","volume":"45","author":"Stafford","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2023112113304126800_bib141","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s11096-013-9796-6","article-title":"Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital","volume":"35","author":"Thanimalai","year":"2013","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"2023112113304126800_bib142","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/02813430601183108","article-title":"Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics","volume":"25","author":"Wallvik","year":"2007","journal-title":"Scand J Prim Health Care"},{"issue":"6","key":"2023112113304126800_bib143","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/j.1875-9114.1995.tb02889.x","article-title":"Outcome analysis of a pharmacist-managed anticoagulation service","volume":"15","author":"Wilt","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2023112113304126800_bib144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/B:THRO.0000003325.62542.43","article-title":"A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care","volume":"15","author":"Witt","year":"2003","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2023112113304126800_bib145","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"issue":"1","key":"2023112113304126800_bib146","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2296-12-88","article-title":"Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic","volume":"12","author":"Young","year":"2011","journal-title":"BMC Fam Pract"},{"issue":"1","key":"2023112113304126800_bib147","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ahj.2008.02.009","article-title":"Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial","volume":"156","author":"Lalonde","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"2023112113304126800_bib148","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s11096-016-0357-7","article-title":"Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore","volume":"38","author":"Chua","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"2023112113304126800_bib149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1525-1497.2000.01239.x","article-title":"The cost-effectiveness of different management strategies for patients on chronic warfarin therapy","volume":"15","author":"Lafata","year":"2000","journal-title":"J Gen Intern Med"},{"issue":"5","key":"2023112113304126800_bib150","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jvs.2011.05.021","article-title":"Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care","volume":"54","author":"Aziz","year":"2011","journal-title":"J Vasc Surg"},{"issue":"6","key":"2023112113304126800_bib151","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/intqhc\/mzx109","article-title":"Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a medical center in Taiwan","volume":"29","author":"Chang","year":"2017","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"2023112113304126800_bib152","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jth.12107","article-title":"Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis","volume":"11","author":"Wong","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2023112113304126800_bib153","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2105\/AJPH.62.8.1135","article-title":"Evaluation of the use of programmed instruction for patients maintained on Warfarin therapy","volume":"62","author":"Clark","year":"1972","journal-title":"Am J Public Health"},{"issue":"9","key":"2023112113304126800_bib154","doi-asserted-by":"crossref","first-page":"e74037","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2023112113304126800_bib155","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0037-1613374","article-title":"Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial","volume":"89","author":"Laporte","year":"2003","journal-title":"Thromb Haemost"},{"issue":"2","key":"2023112113304126800_bib156","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pec.2014.05.008","article-title":"The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: a pilot study","volume":"96","author":"Marini","year":"2014","journal-title":"Patient Educ Couns"},{"issue":"1-3","key":"2023112113304126800_bib157","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pec.2007.08.010","article-title":"Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective?","volume":"69","author":"Mazor","year":"2007","journal-title":"Patient Educ Couns"},{"issue":"9","key":"2023112113304126800_bib158","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s11606-008-0690-1","article-title":"EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study","volume":"23","author":"Pernod","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"37","key":"2023112113304126800_bib159","first-page":"607","article-title":"Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice","volume":"111","author":"Vormfelde","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"2023112113304126800_bib160","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2023112113304126800_bib161","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research","volume":"42","author":"DiMatteo","year":"2004","journal-title":"Med Care"},{"issue":"11","key":"2023112113304126800_bib162","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/pds.4094","article-title":"A randomized trial of lottery-based incentives and reminders to improve warfarin adherence: the Warfarin Incentives (WIN2) Trial","volume":"25","author":"Kimmel","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2023112113304126800_bib163","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ahj.2012.05.005","article-title":"Randomized trial of lottery-based incentives to improve warfarin adherence","volume":"164","author":"Kimmel","year":"2012","journal-title":"Am Heart J"},{"issue":"10","key":"2023112113304126800_bib164","first-page":"625","article-title":"A visual medication schedule to improve anticoagulation control: a randomized, controlled trial","volume":"33","author":"Machtinger","year":"2007","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"45","key":"2023112113304126800_bib165","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.15585\/mmwr.mm6645a2","article-title":"CDC grand rounds: improving medication adherence for chronic disease management - innovations and opportunities","volume":"66","author":"Neiman","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2023112113304126800_bib166","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"2023112113304126800_bib167","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.112.105221","article-title":"Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates","volume":"126","author":"Siegal","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"2023112113304126800_bib168","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamainternmed.2015.1843","article-title":"Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures","volume":"175","author":"Clark","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"22","key":"2023112113304126800_bib169","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N Engl J Med"},{"issue":"28","key":"2023112113304126800_bib170","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"2023112113304126800_bib171","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jth.13178","article-title":"Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure","volume":"14","author":"Douketis","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2023112113304126800_bib172","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.thromres.2015.08.006","article-title":"Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations","volume":"136","author":"Godier","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"2023112113304126800_bib173","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hrthm.2012.12.011","article-title":"Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation","volume":"10","author":"Kim","year":"2013","journal-title":"Heart Rhythm"},{"issue":"3","key":"2023112113304126800_bib174","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.115.015688","article-title":"Perioperative management of dabigatran: a prospective cohort study","volume":"132","author":"Schulman","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"2023112113304126800_bib175","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9241","key":"2023112113304126800_bib176","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(00)03125-1","article-title":"Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial","volume":"356","author":"Crowther","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"2023112113304126800_bib177","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2005.05.022","article-title":"A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves","volume":"46","author":"Ageno","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2023112113304126800_bib178","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00001721-200101000-00002","article-title":"Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study","volume":"12","author":"Fondevila","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2023112113304126800_bib179","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/0003-4819-150-5-200903030-00005","article-title":"Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial","volume":"150","author":"Crowther","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023112113304126800_bib180","first-page":"48","article-title":"Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial","volume":"88","author":"Ageno","year":"2002","journal-title":"Thromb Haemost"},{"issue":"11","key":"2023112113304126800_bib181","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/phar.1343","article-title":"Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study","volume":"33","author":"Bussey","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2023112113304126800_bib182","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb Haemost"},{"issue":"5","key":"2023112113304126800_bib183","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00006123-199911000-00020","article-title":"Use of factor IX complex in warfarin-related intracranial hemorrhage","volume":"45","author":"Boulis","year":"1999","journal-title":"Neurosurgery"},{"issue":"11","key":"2023112113304126800_bib184","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"2023112113304126800_bib185","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"2023112113304126800_bib186","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11239-015-1330-3","article-title":"3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study","volume":"42","author":"Jones","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"14","key":"2023112113304126800_bib187","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1016\/j.clinthera.2011.01.011","article-title":"Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom","volume":"32","author":"Guest","year":"2010","journal-title":"Clin Ther"},{"issue":"15","key":"2023112113304126800_bib188","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"2023112113304126800_bib189","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2017.01.041","article-title":"Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: the SAMURAI-NVAF study","volume":"375","author":"Yoshimura","year":"2017","journal-title":"J Neurol Sci"},{"issue":"1","key":"2023112113304126800_bib190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"issue":"6","key":"2023112113304126800_bib191","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.wneu.2015.08.042","article-title":"Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors","volume":"84","author":"Grandhi","year":"2015","journal-title":"World Neurosurg"},{"issue":"5","key":"2023112113304126800_bib192","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"issue":"3","key":"2023112113304126800_bib193","first-page":"429","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"issue":"12","key":"2023112113304126800_bib194","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2023112113304126800_bib195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2023112113304126800_bib196","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000452096","article-title":"Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran","volume":"8","author":"Held","year":"2016","journal-title":"Case Rep Neurol"},{"issue":"5","key":"2023112113304126800_bib197","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2023112113304126800_bib198","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11239-010-0482-4","article-title":"Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis","volume":"30","author":"De Luca","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2023112113304126800_bib199","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamasurg.2015.3592","article-title":"Use of protamine for anticoagulation during carotid endarterectomy: a meta-analysis","volume":"151","author":"Newhall","year":"2016","journal-title":"JAMA Surg"},{"issue":"4","key":"2023112113304126800_bib200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1078-5884(97)80082-2","article-title":"Should heparin be reversed after carotid endarterectomy? A randomised prospective trial","volume":"13","author":"Fearn","year":"1997","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"10","key":"2023112113304126800_bib201","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0002-9149(97)00676-0","article-title":"In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation","volume":"80","author":"Pan","year":"1997","journal-title":"Am J Cardiol"},{"issue":"1","key":"2023112113304126800_bib202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2004.11.021","article-title":"Impact of heparin neutralization by protamine on restenosis after coronary stent implantation","volume":"105","author":"Kaneda","year":"2005","journal-title":"Int J Cardiol"},{"issue":"3","key":"2023112113304126800_bib203","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0741-5214(95)70140-0","article-title":"Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine","volume":"22","author":"Mauney","year":"1995","journal-title":"J Vasc Surg"},{"issue":"1","key":"2023112113304126800_bib204","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s100169900222","article-title":"Relationship of protamine dosing with postoperative complications of carotid endarterectomy","volume":"13","author":"Levison","year":"1999","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"2023112113304126800_bib205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejvs.2008.01.021","article-title":"Is heparin reversal with protamine after carotid endarterectomy dangerous?","volume":"36","author":"Dellagrammaticas","year":"2008","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"2023112113304126800_bib206","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jvs.2009.10.078","article-title":"Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke","volume":"51","author":"Stone","year":"2010","journal-title":"J Vasc Surg"},{"issue":"5","key":"2023112113304126800_bib207","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00268-013-2347-4","article-title":"Using protamine can significantly reduce the incidence of bleeding complications after carotid endarterectomy without increasing the risk of ischemic cerebral events","volume":"38","author":"Mazzalai","year":"2014","journal-title":"World J Surg"},{"issue":"2","key":"2023112113304126800_bib208","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.avsg.2013.04.011","article-title":"Predictors of cervical bleeding after carotid endarterectomy","volume":"28","author":"Morales Gisbert","year":"2014","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"2023112113304126800_bib209","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0741-5214(90)90046-D","article-title":"The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma","volume":"12","author":"Treiman","year":"1990","journal-title":"J Vasc Surg"},{"issue":"6","key":"2023112113304126800_bib210","first-page":"291","article-title":"Risk factors of stroke in carotid endarterectomy [in Portuguese]","volume":"52","author":"Salles","year":"1997","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"issue":"33","key":"2023112113304126800_bib211","first-page":"2650","article-title":"Clinical observation of neutralizing heparin with protamine in carotid endarterectomy [in Chinese]","volume":"93","author":"Liu","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"2023112113304126800_bib212","first-page":"66","article-title":"In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention","volume":"1","author":"Thuesen","year":"2005","journal-title":"EuroIntervention"},{"issue":"13","key":"2023112113304126800_bib213","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1517\/14656566.8.13.2017","article-title":"Immediate removal of femoral-sheath following protamine administration in patients undergoing intracoronary paclitaxel-eluting-stent implantation","volume":"8","author":"Rossi","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2023112113304126800_bib214","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1161\/STROKEAHA.113.001188","article-title":"Protamine does not increase risk of stroke in patients with elective carotid stenting","volume":"44","author":"McDonald","year":"2013","journal-title":"Stroke"},{"issue":"3","key":"2023112113304126800_bib215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF03187399","article-title":"Cervical wound hematoma after carotid endarterectomy","volume":"3","author":"Welling","year":"1989","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"2023112113304126800_bib216","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1160\/TH15-01-0063","article-title":"Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis","volume":"114","author":"Chai-Adisaksopha","year":"2015","journal-title":"Thromb Haemost"},{"key":"2023112113304126800_bib217","first-page":"463767","article-title":"Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome","volume":"2014","author":"Chen","year":"2014","journal-title":"BioMed Res Int"},{"issue":"10","key":"2023112113304126800_bib218","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archneur.65.10.1313","article-title":"Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage","volume":"65","author":"Claassen","year":"2008","journal-title":"Arch Neurol"},{"issue":"1","key":"2023112113304126800_bib219","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000351151","article-title":"Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy","volume":"36","author":"Gathier","year":"2013","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"2023112113304126800_bib220","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3171\/2015.2.JNS141889","article-title":"Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study","volume":"124","author":"Guha","year":"2016","journal-title":"J Neurosurg"},{"issue":"1","key":"2023112113304126800_bib221","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/STROKEAHA.116.015150","article-title":"Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation","volume":"48","author":"Hernandez","year":"2017","journal-title":"Stroke"},{"issue":"3","key":"2023112113304126800_bib222","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH16-07-0498","article-title":"Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis","volume":"117","author":"Majeed","year":"2017","journal-title":"Thromb Haemost"},{"issue":"1","key":"2023112113304126800_bib223","first-page":"31","article-title":"Subdural hematoma and oral anticoagulation: a therapeutic dilemma from the neurosurgical point of view","volume":"77","author":"Mirzayan","year":"2016","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"issue":"4","key":"2023112113304126800_bib224","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","article-title":"Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation","volume":"177","author":"Nielsen","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1-2","key":"2023112113304126800_bib225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2015.10.031","article-title":"A multicenter, prospective, observational study of warfarin-associated intracerebral hemorrhage: the SAMURAI-WAICH study","volume":"359","author":"Osaki","year":"2015","journal-title":"J Neurol Sci"},{"issue":"4","key":"2023112113304126800_bib226","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"issue":"2","key":"2023112113304126800_bib227","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ajg.2014.398","article-title":"The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study","volume":"110","author":"Sengupta","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2023112113304126800_bib228","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1179\/1743132813Y.0000000275","article-title":"Warfarin associated intracerebral hemorrhage in Hong Kong Chinese","volume":"36","author":"Teo","year":"2014","journal-title":"Neurol Res"},{"issue":"5","key":"2023112113304126800_bib229","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.thromres.2015.10.002","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage","volume":"136","author":"Witt","year":"2015","journal-title":"Thromb Res"},{"issue":"19","key":"2023112113304126800_bib230","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"issue":"8","key":"2023112113304126800_bib231","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"2023112113304126800_bib232","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"issue":"1","key":"2023112113304126800_bib233","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cjca.2011.10.002","article-title":"Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study","volume":"28","author":"Yung","year":"2012","journal-title":"Can J Cardiol"},{"issue":"suppl 2","key":"2023112113304126800_bib234","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"2023112113304126800_bib235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/22\/3257\/2090578\/blooda-30611-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/22\/3257\/2090578\/blooda-30611-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:22:08Z","timestamp":1775283728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/22\/3257\/16107\/American-Society-of-Hematology-2018-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":235,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,11,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018024893","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734504638.793569797","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.734504638.793569468","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]}}}